


PRODUCT INFORMATION



CCG-100602

Item No. 10787

CAS Registry No.: 1207113-88-9
Formal Name: 1-[3,5-bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)-3-piperidinecarboxamide
MF: C₂₁H₁₇ClF₆N₂O₂
FW: 478.8
Purity: ≥98%
UV/Vis.: λ_{max}: 250 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CCG-100602 is supplied as a crystalline solid. A stock solution may be made by dissolving the CCG-100602 in the solvent of choice, which should be purged with an inert gas. CCG-100602 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of CCG-100602 in ethanol is approximately 0.2 mg/ml and approximately 20 mg/ml in DMSO and DMF.

Description

The Rho family of small GTPases play an important role in transduction of cell signaling events associated with several human cancers. CCG-1423 is a specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription. The site of inhibition in the pathway is not precisely defined but CCG-1423 appears to act on some aspect of the interaction of SRF with its transcriptional cofactor megakaryoblastic leukemia 1 (MKL1) at a point upstream of DNA binding.¹ CCG-100602 is a CCG-1423 analog developed for improved selectivity, potency, and attenuated cytotoxicity relative to its parent compound. CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells with an IC₅₀ value of 9.8 μM. At 100 μM, CCG-100602 demonstrates 72% inhibition of PC-3 cell invasion into a Matrigel model of metastasis, exhibiting an efficacy:toxicity profile superior to that of CCG-1423 at 10 μM.²

References

1. Evelyn, C.R., Wade, S.M., Wang, Q., et al. CCG-1423: A small-molecule inhibitor of RhoA transcriptional signaling. *Mol. Cancer Ther.* **6(8)**, 2249-2260 (2007).
2. Evelyn, C.R., Bell, J.L., Ryu, J.G., et al. Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. *Bioorg. Med. Chem. Lett.* **20(2)**, 665-672 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/08/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM